Boy Who Got Unapproved Drug Heads Home to Virginia

PHOTO: Josh Hardy, the 8-year-old whose parents pleaded for an unapproved drug to save his live last spring, can finally go home to Virginia after 6 and a half months living in or near St. Judes Children Hospital in Tennessee.
Share
Copy

Josh Hardy, the boy whose parents successfully fought to get him an unapproved drug to save his life last March, is heading home to Virginia after spending months living in Tennessee to be near St. Jude’s Children’s Hospital.

“Glory to GOD!” his mother, Aimee Hardy, wrote on the Save Josh Facebook page. “We are going home!!!! Leaving today. After 6 1/2 months, Josh finally gets to be in his house.”

PHOTO: A photo of Josh Hardy and his family, after his release from the hospital
#SaveJosh/Facebook
PHOTO: A photo of Josh Hardy and his family, after his release from the hospital

Hardy, 8, has beaten cancer four times, his parents said. But the treatments left his immune system so weak that a common virus became life-threatening.

The Hardy family said that their best hope for Josh’s survival was an unapproved antiviral drug called brincidofovir, but the company that makes the drug at first refused to give it to him. The Hardys started several online petitions to change the company’s mind.

"Having survived four diagnoses of cancer, it would be an absolute travesty for him to meet his demise from a virus," mom Aimee Hardy told ABCNews.com in March. "Especially knowing there is a medicine in someone’s hands that can rid of this virus."

Push to Get Experimental Drugs With Social Media Pressure on the Rise

PHOTO: Josh Hardy, 7, has beat cancer four times, but a virus could kill him.
Courtesy Aimee Hardy
PHOTO: Josh Hardy, 7, has beat cancer four times, but a virus could kill him.

Family Petitions For Unapproved Drug To Save Son

Dying Boy to Get Unapproved Drug After Family's Plea

Josh received his first cancer diagnosis when he was just a baby: Aggressive rhabdoid tumors in both kidneys, Hardy said. He went through surgery, chemotherapy and radiation, but the cancer returned in his thalamus gland and then his lung.

Then, after nearly four years of being cancer-free, Josh received bad news in November 2013, Hardy said. He had myelodysplastic syndrome, the same precancerous bone marrow disorder that ABC News anchor Robin Roberts was diagnosed with in 2012. It can be caused by cancer treatments.

Josh underwent a bone marrow transplant to remedy the disorder, but he developed graft-versus-host disease, meaning the new immune cells started to attack his body, Hardy said. "He was in complete heart failure and kidney failure and went into the ICU on January 14," Hardy said.

To stop the attack, Josh’s doctors at St. Jude Children’s Hospital in Tennessee suppressed his immune system with drugs, allowing his heart and kidneys to start healing. But with a weakened immune system, Josh came down with adenovirus, a common virus that causes colds but can also be much more serious, Hardy said.

In Josh’s case, reawakening his immune system to fight the virus could bring back his graft versus host disease, so doctors gave him an antiviral medicine to get rid of the adenovirus. But the drug was toxic to his kidneys and wasn’t working, Hardy said.

"He’s at a physical standstill," Hardy said at the time.

That was when Josh’s doctor at St. Jude suggested brincidofovir, a drug that researchers at Chimerix, a small North Carolina drug company, have been developing for the past 14 years. St. Jude had been involved in a clinical trial of brincidofovir in which children who had undergone bone marrow transplants and had early adenovirus infections took the drug and were able to decrease the amount of virus in their bodies.

But Dr. Hervé Momméja-Marin, Chimerix vice president of clinical research, said the drug has not been proven to do this in more advanced adenovirus cases, like Josh’s. Chimerix President and CEO Kenneth Moch said giving the drug to Josh would mean they would have to give the drug to the hundreds of other patients hoping to get it under the FDA's compassionate use rules, which allow patients to get drugs even if they aren’t enrolled in clinical trials.

"We all have great compassion for this child," Moch told ABCNews.com March 11. "We spent our lives trying to develop new medications for patients just like Josh… We need to make sure to get this drug available as soon as possible to as many people as possible."

But the following day, Chimerix announced that Josh’s story accelerated talks with the Food and Drug Administration, allowing it to launch a 20-patient open-label clinical trial. Josh was the first patient enrolled.

Moch resigned from his position in April, Chimerix announced.

After months in the hospital, Josh was discharged in April. But persistent problems with his kidney, lung and heart function and the need for several blood transfusions kept the family in Tennessee. Now that those problems are resolved, the family can return to Fredericksburg, Virginia.

“And with a lot of hard work his strength will return,” Aimee Hardy wrote. “He can walk a nice distance holding my hands. And we anticipate the return of his immunity in a few months.”

Join the Discussion
blog comments powered by Disqus
 
You Might Also Like...